Loss of Phosphatase and Tensin Homologue (PTEN) Expression Associated with Higher Risk Grade Group Gleason Prostate Adenocarcinoma in Sanglah Hospital Denpasar
DOI : 10.33371/ijoc.v13i4.680
Background: Prostate cancer is the second most common malignancy in men and the fifth most common cause of death worldwide. In Asia, 59.3% of patients come for the advanced stage treatment. PTEN inactivation is identified in about 20% of primary prostate tumors in radical prostatectomy and the loss of PTEN is associated with poor clinical and pathological outcomes. The purpose of this study is to prove that there is an association between PTEN expression and risk grade group Gleason prostate adenocarcinoma in Sanglah Public Hospital, Denpasar.
Methods: This is a cross-sectional study. The sample size of this study was 35 paraffin blocks. These samples were selected by proportional stratified random sampling from hematoxylin-eosin preparation. Prostate adenocarcinoma was regrouped into 3 categories based on NCCN risk stratification: low risk grade group Gleason (Gleason score ≤ 6), intermediate risk grade group Gleason (Gleason score 7), and high-risk grade group Gleason (Gleason score 8–10). Immunohistochemistry examination of PTEN was performed and the expression was evaluated by scoring method. The data were analyzed by Chi-square and logistic regression.
Results: The analysis result showed that there is an association between PTEN expression and risk grade group Gleason that is statistically significant. The loss of PTEN expression associated with higher risk grade group Gleason is of the higher proportion with p=0.001; PR 3.339; 95% CI: 1.296–8.599, but there is no association between the proportion loss of PTEN expression heterogeneously or homogeneously and the risk grade group Gleason with p=0.742; PR 0.663; 95% CI: 0.179–2.457.
Conclusions: This study has proved that PTEN expression is associated with higher risk grade group Gleason prostate adenocarcinoma.
- Humprey PA, Amin MB, Berney DM, Billis A, Cao D, Cheng L. Acinar adenocarcinoma. In. Moch H, Humprey PA, Ulbright TM, Reuter VE, editors. WHO Classification of Tumours of the Urinary System and Male Genital Organs. 4th Edition. France: Lyon; 2016. p. 138-162.
- Umbas R, Hardjowijoto S, Mochtar CA, Safriadi F, Soesanto WD, Soedarsp MA, Danarto, Sihombing AT, Hamid AR, Sudoyo AW, Tadjoedin H, Syafei S, Gondhowiardjo S, Munandar A, Kodrat H, Nuhonni SA, Indriani, Pratiwi KBH, Dewi FL, Witjaksono F, Manikam NRM, Octovia LI, Rani NA. Pedoman nasional pelayanan kedokteran kanker prostat. Jakarta: Kementerian Kesehatan Republik Indonesia; 2017.
- McKenney JK. Prostate and Seminal Vesicles. In: Goldblum JR, Lamps LW, McKenney JK, Myers JL, editors. Rosai and Ackerman’s Surgical Pathology. Eleventh edition. Philadelpia: Elsevier; 2018. p.1097-1122.
- Djawaria FPA, Saputra H, Susraini AAAN. Loss of PTEN Expression as a Predictive Factor for Poor Clinical Response of Neoadjuvant Chemotherapy in Triple Negative Breast Cancer. IJSR. 2017;2319-7064.
- Geybels MS, Fang M, Wright JL, Qu X, Bibikova M, Klotzle B. PTEN loss is associated with prostate cancer recurrence and alterations in tumor DNA methylation profiles. Oncotarget. 2017;8(48):84338-84348.
- Jamaspishvili T, Berman DM, Ross AE, Scher HI, Marzo AMD, Squire JA. Clinical implications of PTEN loss in prostate cancer. 2018. Macmillan: Springer Nature Reviews Urology. www.nature.com/nrurol.
- Lotan TL, Wei W, Morais CL, Hawley ST, Fazli L, Coll AH, Troyer D, McKenney JK, Simko J, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, Brooks JD. Pten loss as determined by clinical-grade immunohistochemistry assay is associated with worse recurrence-free survival in prostate cancer. Eur Urol Focus. 2016;2:180–188.
- Hamid AA, Gray KP, Huang Y, Bowden M, Pomerantz M, Loda M. Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy. Eur Urol Oncol. 2018;2(5):475-482.
- Lotan TL, Heumann A, Rico SD, Hicks J, Lecksell K, Koop C. PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort. Oncotarget. 2017;8(39): 65566-65576.
- Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Galluzzi CM, Vickers AJ, Parwani AV, Reuter VE, Fine SW, Eastham JA, Wiklund P, Han M, Reddy CA, Ciezki JP, Nyberg T, Klein EA. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol. 2016;69(3):1-8.
- Trock BJ, Fedor H, Gurel B, Jenkins RB, Knudsen BS, Fine SW, Said JW, Carter HB, Lotan TL, De Marzo AM. PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance. Mod Pathol. 2016;29(7):764-71.
- Hughes C, Murphy A, Martin C, Sheils O, O’Leary J. Molecular pathology of prostate cancer. J Clin Pathol. 2005;58:673–684.
- Epstein JI, Cubilla AL, Humphrey PA. The normal prostate gland. In: Silverberg, S.G., Gardner, W.A., Sobin, L.H., editors. Tumors of the Prostate Gland, Seminal vesicles, Penis, and Scrotum. Fourth Series. Washington: American Registry of Pathology; 2011. p.1-19.
- Lee YR, Chen M, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor: new modes and prospects. Macmillan: Springer Nature Reviews Molecular Cell Biology. 2018.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.